57 results about "Aminosugar" patented technology

A composition for oral delivery of a poorly absorbed drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which alone does not increase absorption of the drug through the intestinal mucosa, but which further increases the absorption of the drug in the presence of the enhancer, and optionally a protector for protecting the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include sucrose fatty acid esters, and illustrative promoters include aminosugars and amino acid derivatives, such as poly(amino acids). Illustrative protectors include methylcellulose, poly(vinyl alcohol), and poly(vinyl pyrrolidone).

Compositions and methods relating to partially hydrolyzed fucoidan for use in dietary supplements and skin-care products are described. Fucoidan from brown seaweeds is partially hydrolyzed and / or sulfonated and then mixed with other ingredients for use as a dietary supplement in beverage, capsule, or tablet form or for use as a skin-care product. Other ingredients that can be included in the dietary supplements include vitamins, minerals, amino acids, carotenoids, flavonoids, antioxidants, aminosugars, glycosaminoglycans, and botanicals. Skin care products according to the present invention comprise partially hydrolyzed fucoidan and a base.

The present invention provides a composition containing a substance being capable of supplying aldehyde-like substances to be used in the field of medicaments, cosmetics, hair care products, etc., that contains a low-molecular weight active substance the stability of which is impaired by the effects of aldehydes and a stabilizer having an amine structure and being capable of absorbing aldehydes, and has an improved stability to aldehyde of said low-molecular weight active the stability of which is impaired by the effects of aldehydes substance; and a method for stabilizing such a low-molecular weight active substance. An example of said stabilizer is an aminosugar or a polymer thereof, an aminosugar alcohol or a polymer thereof, an amino acid or a polymer thereof, a protein or a hydrolysate thereof, an alkylamine, a hydroxyalkylamine, or a salt thereof.

The invention discloses a preparation method of glucosamine sulfate, relating to a compound containing aminosugar. The preparation method of glucosamine sulfate has the advantages that a great deal of sulfate precipitation by-product is avoided being generated and a great deal of organic solvent is avoided being used, the operation is in complete aqueous phase, the production processes are safe, the sulfuric acid removed by the membrane method can be recovered and used, the production cost is reduced, exhaust and waste residue are not produced, the prepared product does not contain sodium, potassium or chlorine, the purity of the product reaches over 95 percent, and the glucosamine sulfate can be used to treat osteoarthritis without usage taboo. The preparation method is characterized in that chitin is adopted as the raw material, and a degradation agent of concentrated sulfuric acid is used to cause the chitin to generate degradation reaction; diluted sulfuric acid is used as a deacetylation agent to cause the degraded chitin to generate deacetylation reaction; the chitin which is not reacted after the deacetylation reaction is filtered, and the unreacted sulfuric acid is removed by the membrane method; and the solution, in which the unreacted sulfuric acid is removed, is decolorized, concentrated and dried, and glucosamine sulfate is obtained.

The present invention relates to treating joint related conditions in mammals by administering an aminosugar, and wherein said treatment specifically prevents, lessens or reverses pathologies associated with the joint condition, said pathologies being selected from the group consisting of synovitis, subchondral bone edema, and cartilage degradation.

The present invention relates to compositions for the protection, treatment and repair of connective tissues in humans and animals comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, including pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, L-ergothionine, one or more avocado / soybean unsaponifiables, and an analgesic, e.g., acetaminophen, and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.

The present invention relates to compositions for the modulation of inflammation in connective tissues in humans and animals and the modulation of markers of such inflammation, including COX-2, TNF-α, IL-1β, iNOS, p38, and chemokines, comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, including pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, L-ergothioneine, methylsulfanylmethane, one or more avocado / soybean unsaponifiables, and an analgesic, e.g., acetaminophen, and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.

The invention relates to combinations of an aminosugar and a beta-2-adrenoceptor agonist, such as salbutamol, for the treatment of diseases associated with hypersensivity and inflamation, in particular hypersensivity skin diseases. The aminosugar is preferably a monosaccharide derivative.

A composition for oral delivery of a poorly absorbed drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which alone does not increase absorption of the drug through the intestinal mucosa, but which further increases the absorption of the drug in the presence of the enhancer, and optionally a protector for protecting the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include sucrose fatty acid esters, and illustrative promoters include aminosugars and amino acid derivatives, such as poly(amino acids). Illustrative protectors include methylcellulose, poly(vinyl alcohol), and poly(vinyl pyrrolidone).

Compositions and methods relating to partially hydrolyzed fiicoidan for use in dietary supplements and skin-care products are described. Fucoidan from brown seaweeds is partially hydrolyzed and / or sulfonated and then mixed with other ingredients for use as a dietary supplement in beverage, capsule, or tablet form or for use as a skin-care product. Other ingredients that can be included in the dietary supplements include vitamins, minerals, amino acids, carotenoids, flavonoids, antioxidants, aminosugars, glycosaminogrycans, and botanicals. Skin care products according to the present invention comprise partially hydrolyzed fiicoidan and a base.

An anti-viral compounds effective against viruses belonging to the Flaviviridae family, wherein the anti-viral compounds are 1,5-dideoxy-1,5-imino-D-glucitol derivative compounds having the general formula (I)wherein R2, R3, R4 and R5 are the same or different and are selected from the group consisting of hydrogen, acyl, benzyl, alkyl, aryl, sulfonyl, phosphonyl, silyl, R6 is at least one of alkyl or branched alkyl, heteroalkyl or aryl, R6′ is a bridging group selected from at least one of bicycle[2.2.1]heptyl, bicycle[3.2.1]octyl, oxa analogs, admonyl and cubyl, n′=2-10, n″=1-10, enantiomers and stereoisomers of said compounds and physiologically acceptable salts or solvates of said compounds, enantiomer or stereoisomer.

A process for preparing compounds of chitosan saccharified with aminosugar, adopts chitosan derivatives, aminosugar derivatives and anhydride derivatives as raw materials to synthesize target products. The process comprises: covalently bonding an anhydride derivative as a bonding arm to an aminosugar derivative, so as to form a monosaccharide derivative having an end group of carboxyl; and then covalently bonding the monosaccharide derivative having an end group of carboxyl to a primary amino group of a chitosan derivative via the carboxyl, so as to form a compound of chitosan saccharified with aminosugar.

The present disclosure relates to a chitosan solution neutralized with amino-sugar carbonate buffering solution or amino-sugar phosphate buffering solution or phosphorylated aminosugar buffering solution. The resulting thermogelling chitosan composition is highly biocompatible, isotonic and has the ability to rapidly turn into gel upon heating to the body temperature. It provides a novel chitosan-based composition to suitable for drug delivery, cell delivery and repair or regeneration of tissues and organs as well as other clinical treatment.

This invention discloses chemically modified polyaminosaccharides, in particular chemically modified chitosans, in the molecular structure of which a predetermined proportion of the amino functional groups is sulfonated by the hydrocarbyl sultone compound via a covalent bond. Such chemically modified polyaminosaccharides may be produced by a process of sulfonating an un-modified polyaminosaccharide having amino functional groups by a hydrocarbyl sultone compound in the presence of an organic solvent under a suitable temperature. Chemically modified chitosans of this invention may be used in a variety of applications, including wound healing.

The invention discloses a pharmaceutical composition for curing chronic nasosinusitis and a preparation method thereof. The pharmaceutical composition contains phlegm-resolving prescription ambroxol hydrochloride and antibiotics which is one of Beta- lactam, aminoglycoside, macrolide, carbostyril, anti-anaerobe and lincomycin, or mixture of one of the antibiotics except the anti-anaerobe and the anti-anaerobe. The composition adopts a sinuses irrigation method to administrate and has the characteristics of convenient use, good validity, high safety and hard recurrence for the cure of the acute nasosinusitis and the chronic nasosinusitis.

An embodiment of the invention provides a composition having one or more active ingredients such as an aminosugar, more particularly, glucosamine, glucosamine salt, and mixtures thereof, and a glycosaminoglycan, more particularly, chondroitin, chondroitin salts, and mixtures thereof having a therapeutic use and is stable for at least 24 months. Additionally, the composition includes a diluent, glidant, and lubricant. The invention also provides a method of treating a connective tissue disease, injury, or condition comprising administering to a mammal any one of the compositions described herein. The composition can be in tablet or capsule form.

The invention relates to a synthetic method of aldehyde dextran, an aldehyde dextran-based coating method, and a preparation method of a microsphere composition. The aldehyde dextran is prepared from haloacetal and glucan through substitution and hydrolysis reactions, generated aldehyde groups are difficult to cross-link, the density of the active groups aldehyde groups is controllable, and the reappearance is good, so monoclonal antibody and protein connection is facilitated. The coating method is characterized in that epoxy ethyl particles are adopted as an initial raw material to substitute traditional carboxyl particles. Organic micromolecules can be used to substitute aminosugar, so the whole coating process is simple, and the coating period is short, so the coating method is suitable for industrial production. The preparation method of the microsphere composition is characterized in that the surfaces of microspheres are coated with the aldehyde dextran to form aldehyde dextran microspheres used for covalent coupling of biological molecules. The preparation method has the advantages of simple process, simple operation and good repeatability.

Incorporation of an aminosugar (e.g., glucosamine) to a preparation make a vitamin B1 stable. The content of the aminosugar is an effective amount to stabilize the vitamin B1, and is, for example, not less than 0.1 part by weight relative to 1 part by weight of the vitamin B1. Incorporation of the aminosugar can improve the disintegrativity of a solid preparation comprising a glycosaminoglycan (a hyaluronic acid, a chondroitin or a salt thereof). The content of aminosugars is not less than 0.1 part by weight relative to 1 part by weight of glycosaminoglycans. The solid preparation can inhibit forming gel masses of glycosaminoglycan and can improve the disintegrativity. Moreover, a joint disorder such as arthralgia can be improved by combination of the vitamin B1 and the glucosamine (e.g., glucosamine or a salt thereof).

The present invention relates to a method of producing a flavor improving agent, comprising heating amino acids or peptides in the presence of amino sugars or a method of improving the flavor of a food or drink with the use of the flavor improving agent. Preferably, the method of improving flavor involves the enhancement of stewed taste of a stewed food or drink. In addition, the present invention relates to a method of producing a stewed food or drink, comprising a step of adding amino sugars to a food or drink material containing amino acids or peptides followed by heat cooking. Examples of amino sugars are glucosamine and galactosamine.

A method for producing antibiotic / antibiotics-particles characterized in that an aqueous solution of an amino glycoside-antibiotic or an aqueous solution comprising two or more amino glycoside-antibiotics is mixed under agitation with a solvent mixture comprising isopropanol and at least one additional alcohol, with the volume ratio of the solvent mixture to the aqueous solution being at least 3 to 1 and with the suspension developed being agitated until the primarily yielded coarse antibiotic / antibiotics aggregates disintegrate into particles, which have a grain size smaller than 400 mum.

An ascorbic acid-based composition and related method for the treatment of aging, photo-damaged or inflamed skin is disclosed. The composition includes water and ascorbic acid, at least a portion of which has generally been pretreated by being dissolved under relatively high temperature and concentration conditions. The composition typically includes at least about 5.0% (w / v) ascorbic acid formulated to have a pH above 3.5. 10 to 50% of the ascorbic acid is pretreated ascorbic acid. The composition may also include a non-toxic zinc salt, a tyrosine compound, and / or pharmaceutically acceptable carrier. The composition may include an anti-inflammatory compound, such as aminosugar and / or sulfur-containing anti-inflammatory compound. Embodiments containing an aminosugar such as glucosamine are further useful for treating rosacea and other inflammatory skin ailments. The composition may be administered in a variety of forms suitable for topical application on skin.

The present disclosure relates to a novel enzymatic approach according to the invention using an unprecedented sortase-catalyzed transpeptidation reaction between a substrate comprising LPXTG (SEQ ID NO: 11) peptide motif and biomolecules such as aminosugars, hydroxyamino acids, hydroxyamino acid esters, aminolipids, polyamines; nucleic acids or derivatives thereof; or any molecule having such moieties; or any compound having such moieties to obtain a bioconjugates useful for target delivery of a compound. The present disclosure provides bioconjugates obtained by the novel sortase catalysed transpeptidedation reaction.

The invention relates to the field of medicinal chemistry, an aminosugar derivate, a preparation method and a medical application thereof, in particular to a compound N-(1, 3, 4, 6-fourth-O-galloylhyperin acetyl-2-deoxidizing-beta D-pyranoid galactosyl)-3-(2,4-dichlorophenyl)-acrylamide (I). Pharmacological experiments show that the compound (I) can inhibit the neovascularization of chick chorioallantoic membrane, therefore, the compound can be used for treating tumors or chronic inflammation clinically.

This invention provides a quantitative analysis of glycan biosynthesis along meta pathways using computer simulation for comparing a computer generated spectrum to experimental data to quantitatively track the biosynthesis. Computer simulating the mass spectra of isotopic detection of aminosugars with glutamine experiments allows modeling the glycan biosynthesis over time, via changes in the 14N and 15N isotope abundance levels, to estimate the relative abundance of molecules involved in glycan biosynthesis, from experimental mass spectra. Gradient search optimization is used to maximize the coefficient of determination between the experimental spectrum and the simulated spectrum. These relative abundances are then fed into a pathway simulation model to analyze glycan biosynthesis. Simulating a mass spectrum allows reconfirming the identification, quantifying the isotopic configurations and obtaining the relative abundance of each as samples are taken at periodic intervals, which is then organized to allow tracking the changes in abundance levels over time.

Disclosed is a compound useful as an active ingredient for a pharmaceutical composition having an a-amylase-inhibiting activity, particularly a pharmaceutical composition for the treatment of diabetes. Studies have been made for discovering a compound having an a-amylase-inhibiting activity among the compounds produced by Streptomyces sp. Strain 6982 which is a ray fungus belonging to the genus streptomyces, and it is confirmed that an aminosugar compound has an a-amylase-inhibiting activity. The aminosugar compound has an a-amylase-inhibiting activity, and therefore can be used as a prophylactic or therapeutic agent for diabetes, obesity, NASH (non-alcoholic steatohepatitis), particularly as an ameliorating agent for postprandial blood glucose elevation.

The invention discloses an application of an Htra2 gene expression inhibitor in prevention of acquired sensorineural deafness. The Htra2 gene expression inhibitor is used for preventing ototoxic deafness caused by aminoglycoside antibiotics. The invention also provides a CRISPR / Cas9 gene editing system for preventing the acquired sensorineural deafness, and the CRISPR / Cas9 gene editing system is used for targeting and knocking out the Htra2 gene. The invention proves that the AAV-CRISPR / Cas9-Htra2 gene editing system inner ear microinjection can be used for safely and effectively preventing the ototoxic deafness caused by the aminoglycoside antibiotics.

Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are N-alkylated D-galacto, D-gluco- or L-ido-deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group (“X”) on the methyloxy-carbon. These compounds display an increased inhibitory potency towards GCS, and / or an increased inhibitory potency towards GBA2, and / or a decreased inhibitory potency towards GBA1, relative to known deoxynojirimycin derivatives of the same (D-gluco, L-ido or D-galacto) configuration. Therefore, compounds of the present invention are effective in the treatment of diseases which are associated with an irregular level of cytosolic or lysosomal glucosylceramide and / or higher glycosphingolipids, such as a lysosomal storage disorder, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Sandhoff disease, GM1 gangliosidosis, Sialidosis, Niemann Pick disease type C and AMRF, or a symptom of one of the diseases collectively classed as metabolic syndrome, such as obesity, insulin resistance, hyperlipidemia, hypercholesterolemia, polycystic kidney disease, type II diabetes and chronic inflammation, or a neurodenegerative disorder, such as Parkinson disease or Lewy-body dementia.

The invention discloses a reversible phase change atomized liquid gel containing a hydrocarbyl-amino-glycosyl three-stage glycosyl gelling agent, which comprises the following components in percentageby mass: 0.1-3.0 wt% of a glycosyl gelling agent and 97.0-99.9 wt% of atomized liquid. The chemical structural formula of the glycosyl gelling agent is shown in the specification, wherein R1 and R2 are hydrocarbyl. The atomized liquid gel disclosed by the invention has a thermal reversible phase change characteristic and / or a shear reversible phase change characteristic, the gel-sol phase changetemperature is 135-160 DEG C, and the gel-sol phase change critical shear stress is 55-330Pa. Under heating and / or oscillation, the atomized liquid gel is changed into a sol state from a gel state, and an atomizing agent fixed in the gel is released to form inhalable aerosol; and when heating and / or oscillation is stopped, the sol-state gel rapidly recovers to a gel state, and the atomizing agentwhich is not atomized in the gel is fixed in the gel network again. The atomized liquid gel disclosed by the invention can solve the problem of smoke condensate after suction is stopped and the problem of smoke liquid leakage of an atomizer caused by air pressure change or external force action in transportation.

In vitro process for the proliferation or culture of conjunctive tissue cells selected from the group consisting of chondrocytes, osteoblasts, chondroprogenitor cells, osteoprogenitor cells, tenocytes and ligament cells comprising the step of contacting said cells with an aminosugar selected from the group consisting of mannosamine, N-acetylmannosamine, mannosamine salts and their mixtures. The present invention also relates to compositions which comprise the aminosugar in combination with the cells. These compositions are useful for the treatment of cartilage, bone, tendon and ligament lesions or defects, bone mass losses and osteochondral defects or lesions.